Clinical Trial Update: A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01) [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetic/pharmacodynamic study comparing PF-05280586 to rituximab in rheumatoid arthritis patients with inadequate response to TNF inhibitors com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• PF-05280586
• Rituximab (rituximab)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2019-11-19